Epigallocatechin-3-gallate effectively attenuates skeletal muscle atrophy caused by cancer cachexia

Cancer Letters

Volumn 305, Issue 1, 2011, Pages 40-49

  Wang, Hang ^a   Lai, Ying Jiun ^a   Chan, Yi Lin ^b   Li, Tsung Lin ^c   Wu, Chang Jer ^a  

^a NATIONAL TAIWAN OCEAN UNIVERSITY   (Taiwan)

^b GENOMICS RESEARCH CENTER   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

Cachexia; E3 ligases; EGCG; Muscle wasting; NF B

Indexed keywords

ATROGIN 1; EPIGALLOCATECHIN GALLATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUSCLE RING FINGER 1 PROTEIN; WATER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CACHEXIA; CANCER CACHEXIA; CAUSAL ATTRIBUTION; CELL LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; LEWIS CARCINOMA; LOW DRUG DOSE; MALE; MOUSE; MUSCLE ATROPHY; NONHUMAN; OUTCOME ASSESSMENT; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SKELETAL MUSCLE ATROPHY;

ANIMALS; ANTICARCINOGENIC AGENTS; BLOTTING, WESTERN; CACHEXIA; CARCINOMA, LEWIS LUNG; CATECHIN; FLUORESCENT ANTIBODY TECHNIQUE; MALE; MICE; MICE, INBRED C57BL; MUSCLE PROTEINS; MUSCLE, SKELETAL; MUSCULAR ATROPHY; NF-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SKP CULLIN F-BOX PROTEIN LIGASES; UBIQUITIN-PROTEIN LIGASES;

MUS;

EID: 79953206565     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.02.023     Document Type: Article

References (40)

1. Tisdale M.J. Cachexia in cancer patients. Nat. Rev. Cancer 2002, 2:862-871.
2. Dewys W.D., Begg C., Lavin P.T., Band P.R., Bennett J.M., Bertino J.R., Cohen M.H., Douglass H.O., Engstrom P.F., Ezdinli E.Z., Horton J., Johnson G.J., Moertel C.G., Oken M.M., Perlia C., Rosenbaum C., Silverstein M.N., Skeel R.T., Sponzo R.W., Tormey D.C. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern cooperative oncology group. Am. J. Med. 1980, 69:491-497.
3. Giordano A., Calvani M., Petillo O., Carteni M., Melone M.R., Peluso G. Skeletal muscle metabolism in physiology and in cancer disease. J. Cell Biochem. 2003, 90:170-186.
4. Tawa N.E., Odessey R., Goldberg A.L. Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles. J. Clin. Invest. 1997, 100:197-203.
5. Ciechanover A., Schwartz A.L. The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc. Natl. Acad. Sci. USA 1998, 95:2727-2730.
6. Lecker S.H., Solomon V., Price S.R., Kwon Y.T., Mitch W.E., Goldberg A.L. Ubiquitin conjugation by the N-end rule pathway and mRNAs for its components increase in muscles of diabetic rats. J. Clin. Invest. 1999, 104:1411-1420.
7. Solomon V., Baracos V., Sarraf P., Goldberg A.L. Rates of ubiquitin conjugation increase when muscles atrophy, largely through activation of the N-end rule pathway. Proc. Natl. Acad. Sci. USA 1998, 95:12602-12607.
8. Attaix D., Aurousseau E., Combaret L., Kee A., Larbaud D., Ralliere C., Souweine B., Taillandier D., Tilignac T. Ubiquitin-proteasome-dependent proteolysis in skeletal muscle. Reprod. Nutr. Dev. 1998, 38:153-165.
9. Gomes M.D., Lecker S.H., Jagoe R.T., Navon A., Goldberg A.L. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl. Acad. Sci. USA 2001, 98:14440-14445.
10. Bodine S.C., Latres E., Baumhueter S., Lai V.K., Nunez L., Clarke B.A., Poueymirou W.T., Panaro F.J., Na E., Dharmarajan K., Pan Z.Q., Valenzuela D.M., DeChiara T.M., Stitt T.N., Yancopoulos G.D., Glass D.J. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001, 294:1704-1708.
11. Lecker S.H., Jagoe R.T., Gilbert A., Gomes M., Baracos V., Bailey J., Price S.R., Mitch W.E., Goldberg A.L. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 2004, 18:39-51.
12. Glass D.J. Skeletal muscle hypertrophy and atrophy signaling pathways. Int. J. Biochem. Cell Biol. 2005, 37:1974-1984.
13. Wyke S.M., Tisdale M.J. NF-kappaB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle. Br. J. Cancer 2005, 92:711-721.
14. Wyke S.M., Russell S.T., Tisdale M.J. Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation. Br. J. Cancer 2004, 91:1742-1750.
15. Cai D., Frantz J.D., Tawa N.E., Melendez P.A., Oh B.C., Lidov H.G., Hasselgren P.O., Frontera W.R., Lee J., Glass D.J., Shoelson S.E. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 2004, 119:285-298.
16. Du J., Mitch W.E., Wang X., Price S.R. Glucocorticoids induce proteasome C3 subunit expression in L6 muscle cells by opposing the suppression of its transcription by NF-kappa B. J. Biol. Chem. 2000, 275:19661-19666.
17. Sang S., Lee M.J., Hou Z., Ho C.T., Yang C.S. Stability of tea polyphenol (-)-epigallocatechin-3-gallate and formation of dimers and epimers under common experimental conditions. J. Agric. Food Chem. 2005, 53:9478-9484.
18. Wang Z.Y., Cheng S.J., Zhou Z.C., Athar M., Khan W.A., Bickers D.R., Mukhtar H. Antimutagenic activity of green tea polyphenols. Mutat. Res. 1989, 223:273-285.
19. Lin Y.L., Lin J.K. (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB. Mol. Pharmacol. 1997, 52:465-472.
20. Yang C.S., Wang X., Lu G., Picinich S.C. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat. Rev. Cancer 2009.
21. Yang C.S., Lambert J.D., Hou Z., Ju J., Lu G., Hao X. Molecular targets for the cancer preventive activity of tea polyphenols. Mol. Carcinog. 2006, 45:431-435.
22. Jung Y.D., Ellis L.M. Inhibition of tumour invasion and angiogenesis by epigallocatechin gallate (EGCG), a major component of green tea. Int. J. Exp. Pathol. 2001, 82:309-316.
23. Zhu B.H., Zhan W.H., Li Z.R., Wang Z., He Y.L., Peng J.S., Cai S.R., Ma J.P., Zhang C.H. (-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis. World J. Gastroenterol. 2007, 13:1162-1169.
24. Ahmed S., Marotte H., Kwan K., Ruth J.H., Campbell P.L., Rabquer B.J., Pakozdi A., Koch A.E. Epigallocatechin-3-gallate inhibits IL-6 synthesis and suppresses transsignaling by enhancing soluble gp130 production. Proc. Natl. Acad. Sci. USA 2008, 105:14692-14697.
25. Wheeler D.S., Catravas J.D., Odoms K., Denenberg A., Malhotra V., Wong H.R. Epigallocatechin-3-gallate, a green tea-derived polyphenol, inhibits IL-1 beta-dependent proinflammatory signal transduction in cultured respiratory epithelial cells. J. Nutr. 2004, 134:1039-1044.
26. Chen P.C., Wheeler D.S., Malhotra V., Odoms K., Denenberg A.G., Wong H.R. A green tea-derived polyphenol, epigallocatechin-3-gallate, inhibits IkappaB kinase activation and IL-8 gene expression in respiratory epithelium. Inflammation 2002, 26:233-241.
27. Nakayama G.R., Caton M.C., Nova M.P., Parandoosh Z. Assessment of the Alamar Blue assay for cellular growth and viability in vitro. J. Immunol. Methods 1997, 204:205-208.
28. Dussault A.A., Pouliot M. Rapid and simple comparison of messenger RNA levels using real-time PCR. Biol. Proceed. Online 2006, 8:1-10.
29. Afaq F., Adhami V.M., Ahmad N., Mukhtar H. Inhibition of ultraviolet B-mediated activation of nuclear factor kappaB in normal human epidermal keratinocytes by green tea Constituent (-)-epigallocatechin-3-gallate. Oncogene 2003, 22:1035-1044.
30. Windsor J.A., Hill G.L. Risk factors for postoperative pneumonia. The importance of protein depletion. Ann. Surg. 1988, 208:209-214.
31. Zhang M., Holman C.D., Huang J.P., Xie X. Green tea and the prevention of breast cancer: a case-control study in Southeast China. Carcinogenesis 2007, 28:1074-1078.
32. Yuan J.M., Gao Y.T., Yang C.S., Yu M.C. Urinary biomarkers of tea polyphenols and risk of colorectal cancer in the Shanghai cohort study. Int. J. Cancer 2007, 120:1344-1350.
33. Lu G., Liao J., Yang G., Reuhl K.R., Hao X., Yang C.S. Inhibition of adenoma progression to adenocarcinoma in a 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis model in A/J mice by tea polyphenols and caffeine. Cancer Res. 2006, 66:11494-11501.
34. Landau J.M., Wang Z.Y., Yang G.Y., Ding W., Yang C.S. Inhibition of spontaneous formation of lung tumors and rhabdomyosarcomas in A/J mice by black and green tea. Carcinogenesis 1998, 19:501-507.
35. Sazuka M., Murakami S., Isemura M., Satoh K., Nukiwa T. Inhibitory effects of green tea infusion on in vitro invasion and in vivo metastasis of mouse lung carcinoma cells. Cancer Lett. 1995, 98:27-31.
36. Coussens L.M., Werb Z. Inflammatory cells and cancer: think different!. J. Exp. Med. 2001, 193:F23-26.
37. Argiles J.M., Lopez-Soriano F.J., Busquets S. Mechanisms to explain wasting of muscle and fat in cancer cachexia. Curr. Opin. Support Palliative Care 2007, 1:293-298.
38. Bossola M., Muscaritoli M., Costelli P., Bellantone R., Pacelli F., Busquets S., Argiles J., Lopez-Soriano F.J., Civello I.M., Baccino F.M., Rossi Fanelli F., Doglietto G.B. Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001, 280:R1518-1523.
39. Baracos V.E. Regulation of skeletal-muscle-protein turnover in cancer-associated cachexia. Nutrition 2000, 16:1015-1018.
40. Liang Y.C., Chen Y.C., Lin Y.L., Lin-Shiau S.Y., Ho C.T., Lin J.K. Suppression of extracellular signals and cell proliferation by the black tea polyphenol, theaflavin-3,3'-digallate. Carcinogenesis 1999, 20:733-736.